{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T09:43:00Z","timestamp":1648546980783},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,6,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Purpose<\/jats:title>\n                  <jats:p>The case of a patient who experienced probable infusion-related reactions to amphotericin B lipid complex (ABLC) but tolerated continued amphotericin B therapy after a switch to an alternative lipid-based formulation is reported.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Summary<\/jats:title>\n                  <jats:p>A 28-year-old immunocompromised man with pneumonia, respiratory failure, and neutropenic fever was initiated on ABLC and other antibiotics for suspected invasive aspergillosis. Due to the patient\u2019s deteriorating renal function, the use of amphotericin B was deemed preferable to the standard therapy for invasive aspergillosis (voriconazole) even though he had experienced likely infusion-related reactions to ABLC on two prior occasions. During the infusion of ABLC, significant increases in the man\u2019s temperature, respiratory rate, systolic blood pressure, and heart rate were observed. Although those symptoms were suspected to be infusion related, it was decided that continuing amphotericin B therapy with an alternative lipid-based form of the drug was the best course of action. After the patient was switched to liposomal amphotericin B one day later, no further infusion-related adverse reactions were noted for the duration of therapy. While this case suggests that adverse reactions to one type of amphotericin B might not occur with the use of an alternative formulation, further research is needed to better define the potential for cross-reactivity among various forms of amphotericin B and related safe-infusion practices.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>A patient with invasive aspergillosis who experienced likely infusion- related reactions to ABLC was able to tolerate continued amphotericin B therapy after a switch to the liposomal formulation.<\/jats:p>\n               <\/jats:sec>","DOI":"10.2146\/ajhp120530","type":"journal-article","created":{"date-parts":[[2013,5,29]],"date-time":"2013-05-29T20:28:19Z","timestamp":1369859299000},"page":"1047-1051","source":"Crossref","is-referenced-by-count":1,"title":["Apparent lack of cross-reactivity for infusion-related reactions between two forms of lipid-based amphotericin B"],"prefix":"10.1093","volume":"70","author":[{"given":"Mitchell S.","family":"Buckley","sequence":"first","affiliation":[{"name":"Department of Pharmacy and Medical Intensive Care Unit, and Director, Postgraduate Year 1 Pharmacy Residency"},{"name":"Banner Good Samaritan Medical Center, Phoenix, AZ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clint S.","family":"Anderson","sequence":"additional","affiliation":[{"name":"Banner Good Samaritan Medical Center, Phoenix, AZ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shardool A.","family":"Patel","sequence":"additional","affiliation":[{"name":"Banner Good Samaritan Medical Center, Phoenix, AZ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melanie J.","family":"Yerondopoulos","sequence":"additional","affiliation":[{"name":"Banner Good Samaritan Medical Center, Phoenix, AZ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura M.","family":"Wicks","sequence":"additional","affiliation":[{"name":"Banner Good Samaritan Medical Center, Phoenix, AZ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary T.","family":"Martin","sequence":"additional","affiliation":[{"name":"Banner Good Samaritan Medical Center, Phoenix, AZ"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","reference":[{"key":"2020071623245906600_b1-0701047","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1164\/rccm.200505-727SO","article-title":"Current approaches to diagnosis and treatment of invasive aspergillosis","volume":"173","author":"Segal","year":"2006","journal-title":"Am J Respir Crit Care Med."},{"key":"2020071623245906600_b2-0701047","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1086\/341401","article-title":"A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients","volume":"35","author":"Bowden","year":"2002","journal-title":"Clin Infect Dis."},{"key":"2020071623245906600_b3-0701047","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1086\/525258","article-title":"Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America","volume":"46","author":"Walsh","year":"2008","journal-title":"Clin Infect Dis."},{"key":"2020071623245906600_b4-0701047","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1086\/376634","article-title":"Amphotericin B: time for a new \u201cgold standard\u201d","volume":"37","author":"Ostrosky-Zeichner","year":"2003","journal-title":"Clin Infect Dis."},{"key":"2020071623245906600_b5-0701047","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/s10096-005-0080-0","article-title":"Adverse effects of antifungal therapies in invasive fungal infections: review and meta-analysis","volume":"25","author":"Girois","year":"2006","journal-title":"Eur J Clin Microbiol Infect Dis."},{"key":"2020071623245906600_b6-0701047","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1034\/j.1399-3062.1999.010406.x","article-title":"Amphotericin B and its new formulations: pharmacologic characteristics, clinical efficacy, and tolerability","volume":"1","author":"Tiphine","year":"1999","journal-title":"Transpl Infect Dis."},{"key":"2020071623245906600_b7-0701047","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1086\/516353","article-title":"Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases","volume":"26","author":"Walsh","year":"1998","journal-title":"Clin Infect Dis."},{"key":"2020071623245906600_b8-0701047","first-page":"635","article-title":"Amphotericin B colloidal dispersion vs. amphotericin B as therapy for invasive aspergillosis","volume":"24","author":"White","year":"1997","journal-title":"Clin Infect Dis."},{"key":"2020071623245906600_b9-0701047","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1086\/517642","article-title":"Life- threatening adverse event after amphotericin B lipid complex treatment in a patient treated previously with amphotericin B deoxycholate","volume":"26","author":"Garnacho-Montero","year":"1998","journal-title":"Clin Infect Dis."},{"key":"2020071623245906600_b10-0701047","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1093\/clinids\/27.5.1342","article-title":"Serious adverse event after unrecognized substitution of one amphotericin B lipid preparation for another","volume":"27","author":"Johnson","year":"1998","journal-title":"Clin Infect Dis."},{"key":"2020071623245906600_b11-0701047","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa020191","article-title":"Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis","volume":"347","author":"Herbrecht","year":"2002","journal-title":"N Engl J Med."},{"key":"2020071623245906600_b12-0701047","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1086\/324620","article-title":"Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis","volume":"34","author":"Denning","year":"2002","journal-title":"Clin Infect Dis."},{"key":"2020071623245906600_b13-0701047","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1086\/374557","article-title":"Voriconazole treatment for less-common, emerging, or refractory fungal infections","volume":"36","author":"Perfect","year":"2003","journal-title":"Clin Infect Dis."},{"key":"2020071623245906600_b14-0701047","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/S0149-2918(03)80125-X","article-title":"A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations","volume":"25","author":"Barrett","year":"2003","journal-title":"Clin Ther."},{"key":"2020071623245906600_b15-0701047","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1185\/030079904125003179","article-title":"Efficacy, safety and cost-effectiveness of amphotericin B lipid complex (ABLC): a review of the literature","volume":"20","author":"Martino","year":"2004","journal-title":"Curr Med Res Opin."},{"key":"2020071623245906600_b16-0701047","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1093\/infdis\/156.5.784","article-title":"Induction of prostaglandin synthesis as the mechanism responsible for the chills and fever produced by infusing amphotericin B","volume":"156","author":"Gigliotti","year":"1987","journal-title":"J Infect Dis."},{"key":"2020071623245906600_b17-0701047","first-page":"456A","article-title":"Amphotericin B treatment of human mononuclear cells: in vitro results in secretion of tumor necrosis factor and interleukin-1","volume":"36","author":"Gelfand","year":"1988","journal-title":"Clin Res."},{"key":"2020071623245906600_b18-0701047","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1093\/infdis\/159.1.113","article-title":"Amphotericin B induces tumor necrosis factor production by murine macrophages","volume":"159","author":"Chia","year":"1989","journal-title":"J Infect Dis."},{"key":"2020071623245906600_b19-0701047","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1128\/AAC.36.5.977","article-title":"Pharmacologic modulation of IL-1 expression by amphotericin B-stimulated human mononuclear cells","volume":"36","author":"Cleary","year":"1992","journal-title":"Antimicrob Agents Chemother."},{"key":"2020071623245906600_b20-0701047","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1086\/315004","article-title":"Amphotericin B-induced interleukin-1beta expression in human monocytic cells is calcium and calmodulin dependent","volume":"180","author":"Rogers","year":"1999","journal-title":"J Infect Dis."},{"key":"2020071623245906600_b21-0701047","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther."}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/70\/12\/1047\/28363895\/ajhp1047.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/70\/12\/1047\/28363895\/ajhp1047.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T12:19:21Z","timestamp":1594988361000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/70\/12\/1047\/5112228"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6,15]]},"references-count":21,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2013,6,15]]}},"URL":"https:\/\/doi.org\/10.2146\/ajhp120530","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2013,6,15]]},"published":{"date-parts":[[2013,6,15]]}}}